Journal Article

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

Walker, John, Rutkowski, Piotr, Hill, Andrew G., Hodi, F. Stephen, Lao, Christopher D., Wang, Wenjia, Nassar, Ayman, Guidoboni, Massimo, Butler, Marcus O., Postow, Michael A., Carlino, Matteo S., Márquez-Rodas, Iván, Maio, Michele, Gaudy-Marqueste, Caroline, Queirolo, Paola, Schöffski, Patrick, Schadendorf, Dirk, Benito, Melanie Pe, Larkin, James, Chiarion-Sileni, Vanna, Askelson, Margarita, Sandhu, Shahneen, Dummer, Reinhard, Wolchok, Jedd D., Haanen, John B.A.G., Lebbé, Céleste, Ascierto, Paolo A., Ritchings, Corey, Cowey, C. Lance, Medina, Theresa, Wagstaff, John, Long, Georgina V.

2025

Overview

Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions. We randomly assigned patients with previously untreated advanced melanoma, in a 1:1:1 ratio, to one of the following regimens: nivolumab (1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks; nivolumab (3 mg per kilogram) every 2 weeks plus placebo; or ipilimumab (3 mg per kilogram) every 3 weeks for four doses plus placebo. Treatment was continued until the occurrence of disease progression, unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to mutation status, metastasis stage, and programmed death ligand 1 expression. Here, we report the final, 10-year results of this trial, including results for overall survival and melanoma-specific survival, as well as durability of response. With a minimum follow-up of 10 years, median overall survival was 71.9 months with nivolumab plus ipilimumab, 36.9 months with nivolumab, and 19.9 months with ipilimumab. The hazard ratio for death was 0.53 (95% confidence interval [CI], 0.44 to 0.65) for nivolumab plus ipilimumab as compared with ipilimumab and was 0.63 (95% CI, 0.52 to 0.76) for nivolumab as compared with ipilimumab. Median melanoma-specific survival was more than 120 months with nivolumab plus ipilimumab (not reached, with 37% of the patients alive at the end of the trial), 49.4 months with nivolumab, and 21.9 months with ipilimumab. Among patients who had been alive and progression-free at 3 years, 10-year melanoma-specific survival was 96% with nivolumab plus ipilimumab, 97% with nivolumab, and 88% with ipilimumab. The final trial results showed a continued, ongoing survival benefit with nivolumab plus ipilimumab and with nivolumab monotherapy, as compared with ipilimumab monotherapy, in patients with advanced melanoma. (Funded by Bristol Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).

• Publisher: Massachusetts Medical Society
• Subject: Adolescent / Adult / Aged / Aged, 80 and over / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Body weight / Clinical outcomes / Dermatology / Double-Blind Method / Female / Hematology / Humans / Immunotherapy / Ipilimumab - administration & dosage / Ipilimumab - adverse effects / Kaplan-Meier Estimate / Male / Melanoma / Melanoma - drug therapy / Melanoma - mortality / Melanoma - secondary / Metastases / Middle Aged / Monoclonal antibodies / Mutation / Neoplasm Staging / Nivolumab - administration & dosage / Nivolumab - adverse effects / Oncology / Placebos / Progression-Free Survival / Proto-Oncogene Proteins B-raf - genetics / Skin Cancer / Skin Neoplasms - drug therapy / Skin Neoplasms - mortality / Skin Neoplasms - pathology / Statistical analysis / Survival / Targeted cancer therapy / Treatments in Oncology / Young Adult